Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion type Assertion NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_head.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion description "[Monocytic MLL-AF9 expressing cells (MM6, THP-1) were hypersensitive to both small-molecule inhibitors targeting Rac1 (EHT 1864, NSC 23766) (IC50EHT�~12.5�?M) and lipid lowering drugs (lovastatin, atorvastatin) (IC50Lova�~7.5�?M) as compared to acute myelocytic leukemia (NOMO-1, HL60) and T cell leukemia (Jurkat) cells (IC50EHT�>30�?M; IC50Lova�>25�?M).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_provenance.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion evidence source_evidence_literature NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_provenance.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion SIO_000772 23624644 NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_provenance.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion wasDerivedFrom befree-20140225 NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_provenance.
- NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_assertion wasGeneratedBy ECO_0000203 NP862532.RAcxat4QBdO6vLmqBXX9hzwm6CuDjWngLJ0imSxtdcPOs130_provenance.